Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 5/20 | 0.59 |
| ▸ | ABL1 | P00519 | 3/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | MET | P08581 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.59 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.59 |
| ▸ | MST1R | Q04912 | 1/20 | 0.59 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603518 | 0.92 | CDK1 (0.58) | CDK9ABL1AURKAMAP4K4LCK | |
| SCHEMBL3600716 | 0.88 | ABL1 (0.55) | CDK9ABL1AURKAMAP4K4LCK | |
| SCHEMBL3611442 | 0.86 | CDK9 (0.70) | CDK9ABL1AURKAMAP4K4LCK | |
| SCHEMBL3603990 | 0.84 | CAMK2D (0.60) | CDK9ABL1CDK5CDK1CDK2 | |
| SCHEMBL3610465 | 0.82 | CAMK2D (0.60) | CDK9ABL1CDK5CDK1CDK2 | |
| SCHEMBL3609785 | 0.81 | CDK1 (0.56) | CDK9ABL1AURKAMAP4K4LCK | |
| SCHEMBL3602838 | 0.81 | CDK4 (0.54) | ABL1PDGFRBGSK3BCDK1CDK2 | |
| SCHEMBL14140620 | 0.81 | ABL1 (0.50) | CDK9ABL1AURKAMAP4K4LCK | |
| SCHEMBL5996833 | 0.80 | ABL1 (0.58) | ABL1AURKAPDGFRBMAPK8GSK3B | |
| SCHEMBL3606676 | 0.79 | ABL1 (0.50) | CDK9ABL1AURKAMAP4K4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| WO-2008079933-A2 | HETEROARYL-HETEROARYL COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER, INFLAMMATION AND VIRAL INFECTIONS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CDK9 3238/4885ABL1 3215/4885AURKA 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.